MAP2K7 and cancer: Our data in the two group C cells support that a combination of a MEK inhibitor and a PI3K (AKT) inhibitor might be effective to various types of cancers with double mutations of K-Ras and PIK3CA. In addition to mutations, copy number gain of oncogenes is also important for “oncogene addiction”.